Skip to search formSkip to main contentSkip to account menu
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
TLDR
Adjunctive exenatide treatment for > or = 3 years in T2DM patients resulted in sustained improvements in glycemic control, cardiovascular risk factors, and hepatic biomarkers, coupled with progressive weight reduction.
View on PubMed
Continuous glucose monitoring: roadmap for 21st century diabetes therapy.
TLDR
This report discusses continuous glucose monitoring in terms of its purposes, technologies, target populations, accuracy, clinical indications, outcomes, and problems.
View on PubMed
Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States
TLDR
This retrospective observational study of laboratory-confirmed COVID-19 adults evaluated glycemic and clinical outcomes in patients with and without diabetes and/or acutely uncontrolled hyperglycemia hospitalized March 1 to April 6, 2020, finding that patients with diabetes and or uncontrolled hyper glycemia had a longer LOS and markedly higher mortality than patients without diabetes.
View on SAGE
Threshold-based insulin-pump interruption for reduction of hypoglycemia.
TLDR
This study showed that over a 3-month period the use of sensor-augmented insulin-pump therapy with the threshold-suspend feature reduced nocturnal hypoglycemia, without increasing glycated hemoglobin values.
View on PubMed
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled…
View on PubMed
Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP).
TLDR
Recommendations from the expert panel regarding the need to standardize glucose profile summary metrics and the value of a uniform glucose report to aid clinicians, researchers, and patients are presented.
View on PubMed
An economic analysis of interventions for diabetes.
TLDR
Widely practiced interventions for patients with diabetes can be clearly cost-saving and Clearly cost-effective, and these practices are attractive from both a medical and an economic perspective.
View on PubMed
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
TLDR
This article compares the pharmacology, indications, contraindications, and adverse effects of the Pfizer/BioNTech and Moderna vaccines, which can protect recipients from a SARS-CoV- 2 infection by formation of antibodies and provide immunity against a Sars- coV-2 infection.
View on PubMed
Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital
TLDR
Randomized controlled trials are needed to determine whether CSII therapy and CGM systems in the hospital are associated with improved clinical outcomes compared with intermittent monitoring and conventional insulin treatment or with a favorable cost-benefit ratio.
View on Publisher
Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline.
TLDR
An evidence-based guideline about where CGM can be beneficial in maintaining target levels of glycemia and limiting the risk of hypoglycemia was developed using the Grading of Recommendations, Assessment, Development, and Evaluation system.
View PDF
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License